Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 0.70 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553260 | 0.90 | ERBB2 (0.71) | ERBB2EGFRKCNH2 | |
| SCHEMBL21563125 | 0.88 | ERBB2 (0.66) | ERBB2EGFR | |
| SCHEMBL21563120 | 0.86 | ERBB2 (0.69) | ERBB2EGFR | |
| SCHEMBL30097878 | 0.85 | ERBB2 (0.67) | ERBB2EGFR | |
| SCHEMBL21551347 | 0.83 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL21563154 | 0.80 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL21563298 | 0.80 | ERBB2 (0.74) | ERBB2EGFR | |
| SCHEMBL21551246 | 0.80 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL24569699 | 0.80 | ERBB2 (0.59) | ERBB2EGFR | |
| SCHEMBL20780984 | 0.80 | ERBB2 (0.59) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822334-B2 | ErbB receptor inhibitors | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-11-03 | — | — | US | disclosed |
| US-20200317669-A1 | ERBB RECEPTOR INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-08 | — | — | US | disclosed |
| WO-2019214634-A1 | ERBB RECEPTOR INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822334-B2 | ErbB receptor inhibitors | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885KCNH2 4382/4885 |
| US-20200317669-A1 | ERBB RECEPTOR INHIBITORS | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885KCNH2 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.